Effect of atorvastatin on systolic and diastolic function in patients with heart failure with reduced ejection fraction (HFrEF)
By
Faris Zvizdić
,
Faris Zvizdić
Department of Cardiology, Clinic for Heart, Blood Vessel and Rheumatic Diseases, Clinical Centre, University of Sarajevo,
Sarajevo, Bosnia and Herzegovina
Department of Cardiology, Clinic for Heart, Blood Vessel and Rheumatic Diseases, Clinical Centre, University of Sarajevo,
Sarajevo, Bosnia and Herzegovina
Aim To investigate the benefit of high-dose lipophilic statin therapy on cardiac remodelling, function and progression of heart failure (HF) in patients with ischemic heart disease. Methods A total of 80 patients with ischemic HF diagnosis were followed during 6 months, and they were divided in two groups. First group (n=40) was treated by high-dose lipophilic statin therapy (atorvastatin 40 mg) and conventional therapy for HF, while the second group (n=40) had no atorvastatin in the therapy. Results In the beginning of study, from all of the observed parameters, only the ratio of flow rates in early and late diastole (E/A ratio) differed between the test groups (p=0.007). After six months, a statistically significant increase in left ventricular end-diastolic diameter (LVIDD) in patients who had not been treated with atorvastatin was found. In the patients treated with atorvastatin, there was a significant reduction in basal right ventricle diameter in diastole and systole (p<0.001 and p<0.001, respectively), and in tricuspid annular plane systolic excursion (TAPSE) (p<0.001); there was a reduction in LVIDD (p<0.001), and an increase of ejection fraction of the left ventricle according to Teicholtz and Simpson (p<0.001 and p<0.001, respectively). Also, there was an increase of deceleration time of early diastolic velocity (DTE) (p<0.05) and a decrease of isovolumic relaxation time (IVRT) (p<0.001). Conclusion The reduction in the right and left ventricle diameters was noted after the six-month atorvastatin therapy. Atorvastatin in the therapy resulted in increased EFLV and better systolic function and should be a part of a therapeutic modality of HF.
Choi H, Park M, Youn J. Update on heart failure management and future directions. Korean J Intern Med. 2019. p. 11–43.
2.
Pinal-Fernandez I, Casal-Dominguez M, Mammen A. Statins: pros and cons. Med Clin (Barc). 2018. p. 398–402.
3.
Correale M, Abruzzese S, Greco C, Concilio M, Biase M, Brunetti N. Pleiotropic effects of statin in therapy in heart failure: a review. Curr Vasc Pharm. 2014. p. 873–84.
4.
Swenne C. Beyond lipid lowering: pleiotropic effects of statins in heart failure. Neth Heart J. 2013. p. 406–7.
5.
Vogiatzi G, Oikonomou E, Siasos G, Tsalamandris S, Briasoulis A, Androulakis E, et al. Statins and inflammation in cardiovascular disease. Curr Pharm Des. 2017.
6.
Wang L, Shi J, Zhang Y. Influences of simvastatin on vascular endothelial function of patients with coronary heart disease complicated with congestive heart failure. Eur Rev Med Pharmacol Sci. 2013. p. 1590–3.
7.
Oikonomou E, Siasos G, Zaromitidou M, Hatzis G, Mourouzis K, Chrysohoou C, et al. Atorvastatin treatment improves endothelial function through endothelial progenitor cells mobilization in ischemic heart failure patients. Atherosclerosis. 2015. p. 159–64.
8.
Li J, Sun Y, Wang L, Li Z, Pan W, Cao H. Comparison of effects of simvastatin versus atorvastatin on oxidative stress in patients with coronary heart disease. Clin Cardiol. 2010. p. 222–7.
9.
Costa S, Couto R, Albino-Teixeira M, Sousa A, T. Statins and oxidative stress in chronic heart failure. Rev Port Cardiol. 2016. p. 41–57.
10.
Niazi M, Galehdar N, Jamshidi M, Mohammadi R, Moayyedkazemi A. A Review of the role of statins in heart failure treatment. Curr Clin Pharmacol. 2020. p. 30–7.
11.
Zhang R, Ma S, Shanahan L, Munroe J, Horn S, Speedie S. Discovering and identifying New York heart association classification from electronic health records. BMC Med Inform Decis Mak. 2018. p. 48.
12.
Selker H, Udelson J, Massaro J, Ruthazer R, Agostino D, Griffith R, et al. Oneyear outcomes of out-of-hospital administration of intravenous glucose, insulin, and potassium (GIK) in patients with suspected acute coronary syndromes (from the IMMEDIATE [Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care] Trial). Am J Cardiol. 2014. p. 1599–605.
13.
Benjo A, El-Hayek G, Messerli F, Dinicolantonio J, Hong M, Aziz E, et al. High dose statin loading prior to percutaneous coronary intervention decreases cardiovascular events: a meta-analysis of randomized controlled trials. Catheter Cardiovasc Interv. 2015. p. 53–60.
14.
Kim C, Choi D. Timing of high intensity statin for acute coronary syndrome: how earlier initiation makes better? J Thorac Dis. 2018. p. 2149–52.
15.
Navarese E, Kowalewski M, Andreotti F, Van Wely M, Camaro C, Kolodziejczak M, et al. Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol. 2014. p. 1753–64.
16.
Cannon C, Braunwald E, Mccabe C, Rader D, Rouleau J, Belder R, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004. p. 1495–504.
17.
Patti G, Cannon C, Murphy S, Mega S, Pasceri V, Briguori C, et al. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies. Circulation. 2011. p. 1622–32.
18.
Schwartz G, Olsson A, Ezekowitz M, Ganz P, Oliver M, Waters D, et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACLE study: a randomized controlled trial. JAMA. 2001. p. 1711–8.
19.
Thompson P, Meredith I, Amerena J, Campbell T, Sloman J, Harris P. Pravastatin in Acute Coronary Treatment (PACT) Investigators. Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial. Am Heart J. 2004.
20.
Bonsu K, Reidpath D, Kadirvelu A. Lipophilic statin versus rosuvastatin (hydrophilic) treatment for heart failure: a meta-analysis and adjusted indirect comparison of randomised trials. Cardiovasc Drugs Ther. 2016. p. 177–88.
21.
Schachter M, Chemical. pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005. p. 117–25.
22.
Kjekshus J, Pedersen T, Olsson A, Faergeman O, Pyörälä K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail. 1997. p. 249–54.
23.
Zhang L, Zhang S, Jiang H, Sun A, Zou Y, Ge J. Effects of statin treatment on cardiac function in patients with chronic heart failure: a meta-analysis of randomized controlled trials. Clin Cardiol. 2011. p. 117–23.
24.
Liu G, Zheng X, Xu Y, Lu J, Hui R, Huang X. Effects of lipophilic statins for heart failure: a meta-analysis of 13 randomised controlled trials. Heart Lung Circ. 2014. p. 970–7.
25.
Vrtovec B, Okrajsek R, Golicnik A, Ferjan M, Starc V, Schlegel T, et al. Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure. J Card Fail. 2008. p. 140–4.
26.
Hobbs F, Roalfe A, Davis R, Davies M, Hare R. Prognosis of all-cause heart failure and borderline left ventricular systolic dysfunction: 5 year mortality follow-up of the echocardiographic heart of Rengland 350 screening study (ECHOES). Eur Heart J. 2007. p. 1128–34.
27.
Wu C, Yeh C, Chiang J, Lin T, Wu Y, Chiang C, et al. Effects of atorvastatin treatment on left ventricular diastolic function in peritoneal dialysis patients-The ALEVENT clinical trial. J Clin Lipidol. 2017. p. 657–66.
28.
Sola S, Mir M, Khan B, Lerakis S, Tandon N. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol. 2006. p. 332–7.
29.
Bielecka-Dabrowa A, Bytyçi I, Haehling V, Anker S, Jozwiak S, Rysz J, et al. Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis. Lipids Health Dis. 2019. p. 188.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
